1 / 8

Highlights of the Day-Plenary Session<br /><br />June 1, 2014<br /><br />Lowell E. Schnipper, M.

Highlights of the Day-Plenary Session<br /><br />June 1, 2014<br /><br />Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting. Why invite a value discussion?. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.

hamal
Download Presentation

Highlights of the Day-Plenary Session<br /><br />June 1, 2014<br /><br />Lowell E. Schnipper, M.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Highlights of the Day-Plenary Session<br /><br />June 1, 2014<br /><br />Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

  2. Why invite a value discussion? Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

  3. Clinically Meaningful Outcomes and Implications for Value (Ellis, et al.,J Clin Oncol. 2014 Apr 20;32(12):1277-80 Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

  4. Moving the Discussion to Value it’s far more than Cost Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

  5. Seeking an Association Between Clinical Benefit, Toxicity and Cost Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

  6. Phase III ALTTO trial <br />The ALTTO trial did not meet its endpoints (DFS): Neither the L + T vs. T comparison nor the T → L vs. T comparison<br /> Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

  7. <br /> Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

  8. E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

More Related